Eton Pharmaceuticals Inc. (ETON)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals Q2 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
Eton Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LN Louis Navellier NAVELLIER & ASSOCIATES Inc. | 18,010 | $661,507.3 | $836,024.2 | $174,516.9 | 26.38% |
| NA Nizar Araji National Bank Of Canada /FI/ | 4 | $146.92 | $178.4 | $31.48 | 21.43% |
| BG Bart Gancher Intech Investment Management LLC | 7,423 | $272,646.79 | $331,065.8 | $58,419.01 | 21.43% |
 Point72 Asset Management LP Point72 Asset Management LP | 44,918 | $1.63M | $2.64M | $1.02M | 62.6% |
 Joseph Castro Nuveen LLC | 375,707 | $12.33M | $16.41M | $4.08M | 33.08% |
Eton Pharmaceuticals Inc. (ETON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Eton Pharmaceuticals Inc. ever had a stock split?
Eton Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sean E. Brynjelsen CEO | NASDAQ (NMS) Exchange | 29772L108 CUSIP |
| US Country | 44 Employees | - Last Dividend | - Last Split | 13 Nov 2018 IPO Date |
Overview
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focused mission of developing, acquiring, and bringing to market pharmaceutical products aimed at treating rare diseases. Founded in 2017 and headquartered in Deer Park, Illinois, Eton Pharmaceuticals identifies unmet medical needs in the rare disease space and addresses them through innovative treatment solutions. The company's strategy underscores its commitment to improving the lives of patients, especially children suffering from complex and rare conditions that require specialized therapeutic interventions.
Products and Services
- ALKINDI SPRINKLE
ALKINDI SPRINKLE stands out as a unique replacement therapy specifically formulated for managing adrenocortical insufficiency in children under the age of 17. This essential treatment offers a lifeline for young patients dealing with this rare condition, ensuring they receive the necessary hormonal support for everyday health and well-being.
- Carglumic Acid
Carglumic Acid is approved for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency. This product plays a critical role in managing a condition that can lead to dangerous levels of ammonia in the blood, presenting a vital solution for affected individuals.
- Betaine Anhydrous
This therapeutic option is targeted at treating homocystinuria, a rare disorder affecting the metabolism of the amino acid methionine. Betaine Anhydrous helps reduce harmful levels of homocysteine in the blood, thereby mitigating potential complications and improving the quality of life for those with homocystinuria.
- Nitisinone
Nitisinone is prescribed for the treatment of hereditary tyrosinemia type 1, a genetic disorder that can lead to severe liver and kidney problems. By using Nitisinone, patients can manage the effects of the condition, preventing significant organ damage and enhancing longevity and life quality.
- Zeneo Hydrocortisone Autoinjector
As a novel solution for the emergency treatment of adrenal crisis, the Zeneo hydrocortisone autoinjector is a significant advancement in the care of patients with chronic adrenal insufficiency. This device empowers patients and caregivers by providing a quick, effective, and easy-to-use means of administering life-saving medication during a crisis.
